{"prompt": "['PROTOCOL SYNOPSIS', 'Names of Sponsor/Company: Vascular Insights, LLC', 'Name of Investigational Product: ClariVein RES (Sodium Tetradecyl Sulfate 1% and 3% Injection', 'delivered via the ClariVein infusion catheter system)', 'Name of Active Ingredient: Sodium tetradecyl sulfate (STS)', 'Name of the Delivery System: ClariVein', 'Study Title: A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein', 'RES for Treatment of Venous Insufficiency Associated with Incompetent Saphenous Veins due to', 'Superficial Venous Reflux (VICARES)', 'Number of Study Centers/Patients: Approximately 10 study centers/50 patients in the USA', 'Study Period:', 'Phase of Development:', \"Estimated date of first patient's consent: Q3 2017\", 'Phase 2 (Pilot)', \"Estimated date of last patient's last visit: Q1 2018\", 'Study Purpose', 'The purpose of the study is to utilize the ClariVein infusion catheter system specifically for delivery', 'of the STS injection to treat venous insufficiency associated with incompetent saphenous veins.', 'Primary Objective', 'Improvement in patient reported symptoms using, HASTI symptoms (heaviness, aching, swelling,', 'throbbing and itching) from the VEINES-QOL/Sym Questionnaire at post treatment Week 12', 'compared to Baseline.', 'Secondary Objective', 'Elimination of saphenous vein reflux post treatment as demonstrated by duplex ultrasound at Week 12', 'post treatment.', 'Tertiary Objectives', 'Assessment of patient improvement at Week 12 post treatment as compared to the Baseline using the', 'following scales:', 'Clinical-Etiology-Anatomy-Pathophysiology (CEAP) Classification', 'European Quality of Life Scale (EQ-5D-5L)', 'Revised Venous Clinical Severity Score (rVCSS)', 'Wong Baker Visual Analog Pain Scale (VAS scale)', 'Study Design:', 'This Phase 2 clinical study is designed as a prospective, randomized, controlled, multicenter, double-', 'Page 10 of 101']['blind study of ClariVein RES for the treatment of venous insufficiency associated with incompetent', 'saphenous veins due to superficial venous reflux.', 'Population:', 'The study will be conducted in adult patients with the diagnosis of incompetent saphenous veins.', 'Inclusion Criteria', 'An individual must meet all the following inclusion criteria to be eligible for this study:', '1. Written informed consent', '2. Age >18 years VI 80', '3. Saphenous vein reflux > 500ms (0.5s), as measured by duplex ultrasound with patient in the', 'standing position', '4. Incompetent saphenous vein with vein diameter > 4 mm and VI 12 mm, as measured by duplex', 'ultrasound with patient in the standing position', '5. Incompetent saphenous vein with treatable length > 10 cm, as measured by duplex ultrasound', 'with patient in the standing position', '6. One or more of the HASTI symptoms related to the target vein: heaviness, achiness, swelling,', 'throbbing and itching.', '7. Candidate for endovenous procedure for the treatment of venous insufficiency or superficial', 'venous reflux.', '8. CEAP Score: C2 (symptomatic), C3, C4, C5', '9. rVCSS > 3', 'Exclusion Criteria', 'An individual will be ineligible for participation in this study if any of the follow criteria are met:', '1. CEAP Score: C1, C2 (asymptomatic), C6', '2. Second incompetent saphenous vein > 4 mm diameter in either leg', '3. Arterial insufficiency demonstrated by a history of peripheral arterial disease (PAD) that', 'would preclude the wearing of compression stockings', '4. Absence of a palpable pulse at posterior tibial or dorsalis pedis and an Ankle-Brachial Index', '(ABI) <0.6', '5. Multi-segmental axial deep venous reflux in at least two contiguous venous segments (e.g.,', 'femoral and popliteal) in the ipsilateral extremity', '6. Previous surgical or endovenous procedure in the treatment section of the target vein (e.g.,', 'surgical, thermal ablation, chemical ablation, etc.)', '7. Any major surgery, prolonged hospitalization, or pregnancy within 12 weeks prior to', 'Screening (Visit 1)', 'Page 11 of 101']\n\n###\n\n", "completion": "END"}